A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)

Abstract

In Part 1 of the phase 3 CASSIOPEIA study, patients (pts) received D-VTd or bortezomib-thalidomide-dexamethasone (VTd) as pre-autologous stem cell transplant (ASCT) induction (four 28-day cycles) and post-ASCT consolidation therapy (two 28-day cycles). D-VTd improved progression-free survival (PFS) and rates of stringent complete response (sCR) and minimal residual disease-negativity rate vs VTd. In Part 2 (ongoing), pts were re-randomized to D maintenance or observation for 2 years. In the phase 3 IFM 2005-01 study, pts received vincristine-doxorubicin-dexamethasone (VAd) induction (four 28-day cycles) with or without dexamethasone-cyclophosphamide-etoposide-cisplatin (dCEP) consolidation (two 28-day cycles), or Vd induction (four 21-day cycles) with or without dCEP consolidation therapy; all pts with a partial response or better post-ASCT were randomized (1:1) to receive lenalidomide maintenance or placebo until relapse.